Colon cancer was a highly heterogeneous disease, resulting from a series of distinct genetic and epigenetic changes, and a subset of molecular alterations was considered to drive the cellular and clinical behavior of cancer, including MSI, CIMP, CIN, BRAF, and KRAS mutations (Marisa et al., 2013; Phipps et al., 2015). This evidence concerns the gene BRAF and colonic neoplasm.